BACKGROUND Non-ST-elevation myocardial infarction(NSTEMI)is a prevalent acute coronary syndrome among the elderly,a population often underrepresented in clinical trials.Frailty,a marker of physiologic vulnerability,ma...BACKGROUND Non-ST-elevation myocardial infarction(NSTEMI)is a prevalent acute coronary syndrome among the elderly,a population often underrepresented in clinical trials.Frailty,a marker of physiologic vulnerability,may influence the risks and benefits of percutaneous coronary intervention(PCI)in these patients.AIM To evaluate the impact of frailty status on in-hospital outcomes among patients aged≥75 years with NSTEMI undergoing PCI.METHODS We conducted a retrospective cohort study using the 2021-2022 National Inpatient Sample to evaluate the impact of frailty on in-hospital outcomes among NSTEMI patients aged≥75 years undergoing PCI.Patients were stratified into three frailty categories using the Hospital Frailty Risk Score.Multivariable logistic and generalized linear models with interaction terms assessed the association between frailty and clinical outcomes.RESULTS Among 456690 NSTEMI admissions,37.95%,50.71%,and 11.34%were categorized as low,intermediate,and high frailty,respectively.PCI use declined with increasing frailty(35.0%in low vs 7.5%in high;P<0.001).Adjusted mortality was lower with PCI across all frailty levels[odds ratios(OR):0.27(low),0.37(intermediate),0.43(high);all P<0.001].However,the mortality benefit was attenuated with increasing frailty(interaction OR:1.56 and 1.83 for intermediate and high vs low frailty;P<0.001).Frailty was independently associated with higher odds of complications,including acute kidney injury,respiratory failure,delirium,and bleeding.PCI was associated with shorter hospital stays in low(-0.90 days)but longer in the high-frail category(+2.47 days;P<0.001),and increasing frailty correlated with significantly higher hospital charges.CONCLUSION In elderly NSTEMI patients,PCI conferred a survival benefit across all frailty strata,although with a diminishing magnitude as frailty increased.Frailty correlated with increased complications and healthcare resource utilization.展开更多
Fecal microbiota transplantation(FMT)offers a potential treatment avenue for hepatic encephalopathy(HE)by leveraging beneficial bacterial displacement to restore a balanced gut microbiome.The prevalence of HE varies w...Fecal microbiota transplantation(FMT)offers a potential treatment avenue for hepatic encephalopathy(HE)by leveraging beneficial bacterial displacement to restore a balanced gut microbiome.The prevalence of HE varies with liver disease severity and comorbidities.HE pathogenesis involves ammonia toxicity,gut-brain communication disruption,and inflammation.FMT aims to restore gut microbiota balance,addressing these factors.FMT's efficacy has been explored in various conditions,including HE.Studies suggest that FMT can modulate gut microbiota,reduce ammonia levels,and alleviate inflammation.FMT has shown promise in alcohol-associated,hepatitis B and C-associated,and non-alcoholic fatty liver disease.Benefits include improved liver function,cognitive function,and the slowing of disease progression.However,larger,controlled studies are needed to validate its effectiveness in these contexts.Studies have shown cognitive improvements through FMT,with potential benefits in cirrhotic patients.Notably,trials have demonstrated reduced serious adverse events and cognitive enhancements in FMT arms compared to the standard of care.Although evidence is promising,challenges remain:Limited patient numbers,varied dosages,administration routes,and donor profiles.Further large-scale,controlled trials are essential to establish standardized guidelines and ensure FMT's clinical applications and efficacy.While FMT holds potential for HE management,ongoing research is needed to address these challenges,optimize protocols,and expand its availability as a therapeutic option for diverse hepatic conditions.展开更多
文摘BACKGROUND Non-ST-elevation myocardial infarction(NSTEMI)is a prevalent acute coronary syndrome among the elderly,a population often underrepresented in clinical trials.Frailty,a marker of physiologic vulnerability,may influence the risks and benefits of percutaneous coronary intervention(PCI)in these patients.AIM To evaluate the impact of frailty status on in-hospital outcomes among patients aged≥75 years with NSTEMI undergoing PCI.METHODS We conducted a retrospective cohort study using the 2021-2022 National Inpatient Sample to evaluate the impact of frailty on in-hospital outcomes among NSTEMI patients aged≥75 years undergoing PCI.Patients were stratified into three frailty categories using the Hospital Frailty Risk Score.Multivariable logistic and generalized linear models with interaction terms assessed the association between frailty and clinical outcomes.RESULTS Among 456690 NSTEMI admissions,37.95%,50.71%,and 11.34%were categorized as low,intermediate,and high frailty,respectively.PCI use declined with increasing frailty(35.0%in low vs 7.5%in high;P<0.001).Adjusted mortality was lower with PCI across all frailty levels[odds ratios(OR):0.27(low),0.37(intermediate),0.43(high);all P<0.001].However,the mortality benefit was attenuated with increasing frailty(interaction OR:1.56 and 1.83 for intermediate and high vs low frailty;P<0.001).Frailty was independently associated with higher odds of complications,including acute kidney injury,respiratory failure,delirium,and bleeding.PCI was associated with shorter hospital stays in low(-0.90 days)but longer in the high-frail category(+2.47 days;P<0.001),and increasing frailty correlated with significantly higher hospital charges.CONCLUSION In elderly NSTEMI patients,PCI conferred a survival benefit across all frailty strata,although with a diminishing magnitude as frailty increased.Frailty correlated with increased complications and healthcare resource utilization.
文摘Fecal microbiota transplantation(FMT)offers a potential treatment avenue for hepatic encephalopathy(HE)by leveraging beneficial bacterial displacement to restore a balanced gut microbiome.The prevalence of HE varies with liver disease severity and comorbidities.HE pathogenesis involves ammonia toxicity,gut-brain communication disruption,and inflammation.FMT aims to restore gut microbiota balance,addressing these factors.FMT's efficacy has been explored in various conditions,including HE.Studies suggest that FMT can modulate gut microbiota,reduce ammonia levels,and alleviate inflammation.FMT has shown promise in alcohol-associated,hepatitis B and C-associated,and non-alcoholic fatty liver disease.Benefits include improved liver function,cognitive function,and the slowing of disease progression.However,larger,controlled studies are needed to validate its effectiveness in these contexts.Studies have shown cognitive improvements through FMT,with potential benefits in cirrhotic patients.Notably,trials have demonstrated reduced serious adverse events and cognitive enhancements in FMT arms compared to the standard of care.Although evidence is promising,challenges remain:Limited patient numbers,varied dosages,administration routes,and donor profiles.Further large-scale,controlled trials are essential to establish standardized guidelines and ensure FMT's clinical applications and efficacy.While FMT holds potential for HE management,ongoing research is needed to address these challenges,optimize protocols,and expand its availability as a therapeutic option for diverse hepatic conditions.
